Big Pharma's Manufacturing Blueprint for the Future - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Big Pharma's Manufacturing Blueprint for the Future
The pharmaceutical majors continue rationalizing manufacturing capacity in established markets as they forge their manufacturing networks in biologics and emerging markets.


Pharmaceutical Technology
Volume 35, Issue 8, pp. 40-47

Other companies. Among other changes in Big Pharma manufacturing networks includes AstraZeneca's construction of a new $150-million manufacturing facility in the Kaluga region in Russia. In June 2011, the company also announced plans to establish a Predictive Science Center in St. Petersburg. In addition, AstraZeneca has established several partnerships with Russian development institutes, including the Skolkovo Innovation Centre and Russia Venture Company. In China, Eli Lilly is building a second manufacturing plant and dedicated diabetes research center. Earlier this year, Boehringer Ingelheim acquired the rights and substantially all the assets at Amgen's Fremont, California, development and manufacturing facility. The Fremont site includes a 100,000-ft2 manufacturing facility with a pilot plant and process-development laboratories. Boehringer Ingelheim will use the facility to enhance its contract-manufacturing activities. The company has been a contract manufacturer for Amgen.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here